Global Hypercholesterolemia Drugs Market 2016-2020

Global Hypercholesterolemia Drugs Market 2016-2020

  • July 2016 •
  • 98 pages •
  • Report ID: 4016636 •
  • Format: PDF
About Hypercholesterolemia

Hypercholesterolemia is characterized by high levels of total cholesterol and LDL-C in the blood. High cholesterol levels can cause CVDs such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL.Blood cholesterol contains individual components such as LDL-C and HDL-C. LDL carries cholesterol to the body and HDL removes cholesterol from the cells by reversing cholesterol transport to the liver.

Technavio’s analysts forecast the global hypercholesterolemia drugs market to decline at a CAGR of 6.78% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global hypercholesterolemia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generics, and off-label drugs used to treat hypercholesterolemia.

The market is divided into the following segments based on geography:
- Americas

Technavio's report, Global Hypercholesterolemia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
- AbbVie
- Aegerion Pharmaceuticals
- AstraZeneca
- Merck
- Pfizer
- Sanofi

Other prominent vendors
- Alnylam Pharmaceuticals
- Amarin
- Amgen
- AtheroNova
- Aurobindo Pharma
- Biocon
- Biospherics
- Bristol-Myers Squibb
- Catabasis Pharmaceuticals
- Cerenis Therapeutics
- Cipla
- CJ HealthCare
- CKD Bio
- Concord Biotech
- CymaBay Therapeutics
- Daewoong Pharmaceutical
- Daiichi Sankyo
- Eli Lilly
- Esperion Therapeutics
- GlaxoSmithKline
- HanAll BioPharma
- JW Pharmaceuticals
- Kadmon Pharmaceuticals
- Kowa Company
- Laboratoires
- Livzon Pharmaceutical
- Lupin Pharmaceuticals
- Madrigal Pharmaceuticals
- Merz Pharmaceuticals
- Mylan
- Novartis
- Regeneron Pharmaceuticals
- ReGenX Biosciences
- Santaris Pharma
- Serometrix
- Sun Pharmaceutical
- Arbutus Biopharma
- Teva Pharmaceuticals
- Torrent Pharmaceuticals
- Zydus Cadila

Market driver
- Rising prevalence of chronic diseases
- For a full, detailed list, view our report

Market challenge
- Loss of patent exclusivity of branded therapies
- For a full, detailed list, view our report

Market trend
- Expected entry of cost-effective OTC versions
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


We are very sorry, but an error occurred.
Please contact if the problem remains.